We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-c... Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Show more
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
AUSTIN, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth...
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.28 | -8.58895705521 | 3.26 | 3.38 | 2.8169 | 27462 | 3.08829402 | CS |
4 | -0.23 | -7.16510903427 | 3.21 | 3.6299 | 2.8169 | 15736 | 3.239674 | CS |
12 | -1.69 | -36.1884368308 | 4.67 | 5 | 2.51 | 22857 | 3.4637079 | CS |
26 | -1.26 | -29.7169811321 | 4.24 | 5.65 | 2.49 | 35733 | 3.75848431 | CS |
52 | -1.61 | -35.0762527233 | 4.59 | 6.75 | 2.3087 | 58686 | 4.02366418 | CS |
156 | -74.87 | -96.1721258831 | 77.85 | 95.85 | 2.3087 | 424714 | 25.06281467 | CS |
260 | -59.12 | -95.2012882448 | 62.1 | 158.1 | 2.3087 | 500826 | 43.97377031 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions